AP
ACOR

AHL Partners’s Acorda Therapeutics ACOR Stock Holding History

AHL Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-228
Closed -$1.17M – 846
2015
Q4 		$1.17M Buy
228
+130
+133% +$568K 0.09% 344
2015
Q3 		$311K Sell
98
-921
-90% -$3.57M 0.05% 547
2015
Q2 		$4.08M Sell
1,019
-82
-7% -$317K 0.16% 277
2015
Q1 		$4.4M Buy
1,101
+703
+177% +$3.22M 0.18% 239
2014
Q4 		$1.95M Buy
+398
New +$1.71M 0.1% 457

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AHL Partners's ACOR Position: Q1 2016 in Review

AHL Partners sold out of Acorda Therapeutics (ACOR) in Q1 2016, closing a stake of 228 shares — an estimated $1.17M sold.

AHL Partners first reported a position in ACOR in Q4 2014 and held it in 5 quarters. The position peaked at $4.4M in Q1 2015. 194 funds tracked by Wall St. Rank hold ACOR as of Q1 2016.

  • AHL Partners reported no remaining Acorda Therapeutics position as of Q1 2016 after selling out during the quarter.
  • AHL Partners sold 228 Acorda Therapeutics shares in Q1 2016, an estimated $1.17M.
  • AHL Partners first reported a position in Acorda Therapeutics in Q4 2014 and held it in 5 quarters.
  • AHL Partners's Acorda Therapeutics position peaked at $4.4M in Q1 2015.
  • 194 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2016.

Based on AHL Partners's 13F filing for Q1 2016, filed 16 May 2016.